VRTX – vertex pharmaceuticals incorporated (US:NASDAQ)
Stock Stats
News
2/6
06:36 am
vrtx
Medium
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at Weiss Ratings from a "hold (c+)" rating to a "buy (b-)" rating.
2/6
03:08 am
vrtx
Medium
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release [Yahoo! Finance]
2/4
08:17 am
vrtx
Low
Jupiter Endovascular Announces Completion of Enrollment in SPIRARE II Pivotal Trial [Yahoo! Finance]
2/3
07:06 pm
vrtx
Low
Here's How Much a $1000 Investment in Vertex Pharmaceuticals Made 10 Years Ago Would Be Worth Today [Yahoo! Finance]
2/2
10:29 pm
vrtx
Low
WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager [Yahoo! Finance]
11/3/2025
04:02 pm
vrtx
-0.9%
BEAT
8/4/2025
04:01 pm
vrtx
-20.6%
BEAT
5/5/2025
04:01 pm
vrtx
-10.0%
BEAT
2/10/2025
04:01 pm
vrtx
-3.1%
BEAT
1/28
09:55 am
Upgrades
Equal-Weight
Overweight
Barclays
Low
1.0%
1/28
09:55 am
Upgrades
Equal-Weight
Overweight
Barclays
Low
1.0%
1/27
05:02 pm
Upgrades
Equal Weight
Overweight
Barclays PLC
Low
2.0%
1/26
12:55 pm
Maintains
Buy
Buy
UBS
Low
-0.1%
1/26
10:02 am
Reiterates
Buy
Buy
UBS Group AG
Low
0.5%
2/3
04:09 pm
vrtx
Low
Form 3 VERTEX PHARMACEUTICALS For: Feb 01 Filed by: Bunnage Mark E.
1/26
04:38 pm
vrtx
Low
Form 4 VERTEX PHARMACEUTICALS For: Jan 22 Filed by: WAGNER CHARLES F JR
1/26
04:37 pm
vrtx
Low
Form 4 VERTEX PHARMACEUTICALS For: Jan 22 Filed by: Tatsis Ourania
1/26
04:35 pm
vrtx
Low
Form 4 VERTEX PHARMACEUTICALS For: Jan 22 Filed by: Sachdev Amit
1/26
04:30 pm
vrtx
Low
Form 4 VERTEX PHARMACEUTICALS For: Jan 22 Filed by: McKechnie Duncan
Show more
Top News Gainers
3/12 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock. 8.1%
4/1 Form 8-K VERTEX PHARMACEUTICALS For: Apr 01 7.7%
3/4 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $271.00 price target on the stock. 7.6%
7/31 Q2/2019 6/30/2019 EPS 1.260 ZacksConsensus 0.750 ActVsEst 0.510 - Beat 7.6%
3/2 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Argus from $248.00 to $270.00. They now have a "buy" rating on the stock. 5.1%
3/28 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "buy" rating re-affirmed by analysts at Piper Sandler. They now have a $300.00 price target on the stock. 5.0%
10/19  Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia 4.1%
10/21 Form 8-K VERTEX PHARMACEUTICALS For: Oct 21 4.1%
4/6 Form SEC STAFF LETTER VERTEX PHARMACEUTICALS 3.8%
4/15 Form 4 VERTEX PHARMACEUTICALS For: Apr 13 Filed by: Silva Paul M 3.7%
Top News Decliners
1/30 Vertex Pharmaceuticals Inc (VRTX) Q4 2019 Earnings Call Transcript [The Motley Fool] -6.8%
4/7 The Vertex Foundation Commits $5 Million to Support Global COVID-19 Pandemic Response -6.2%
3/7 2 Biotech Stocks to Buy as Coronavirus Fears Tank the Market [The Motley Fool] -5.9%
4/28 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by analysts at Royal Bank of Canada from an "outperform" rating to a "sector perform" rating. -5.1%
3/17 Crispr: Beyond Gene-Editing [Seeking Alpha] -5.0%
4/21 Vertex Announces Innovative Reimbursement Agreement in Switzerland for ORKAMBI® (lumacaftor/ivacaftor) and SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Cystic Fibrosis Patients -4.4%
4/30 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at JMP Securities from $255.00 to $285.00. They now have a "market outperform" rating on the stock. -4.1%
2/26 Form 4 VERTEX PHARMACEUTICALS For: Feb 24 Filed by: WAGNER CHARLES F JR -3.8%
9/4 Vertex Pharmaceuticals' $950 Million Bet on Curing Type 1 Diabetes Could Have an Astronomical Payoff [The Motley Fool] -3.7%
5/28 Form 4 VERTEX PHARMACEUTICALS For: May 24 Filed by: LEIDEN JEFFREY M -3.6%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3